Secukinumab vs placebo
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
Secukinumab probably leads to higher proportion of participants with adverse effects serious or severe… compared with placebo (moderate certainty).
1 finding from 1 review
- RR 3.29 [1.4, 7.75]1 study · 157 participantsModerate